Follow the 애드바이오텍 share price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares trade on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 애드바이오텍 has logged 56 public disclosures. Market capitalisation: €40.6bn. The latest transaction was reported on 4 June 2026 (Other). Among the most active insiders: SBI인베스트먼트. Every trade is accessible without an account.
56
Insider Decl.
n/a
Thresholds
n/a
13 ops.
Buy Volume
n/a
33 ops.
Sell Volume
13Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,953 of 29,062 companies
22.7
score / 100
Value
23
Quality
23
FCF yld-3.5%
Earn yld-6.8%
EV/EBITDA·
ROE-80%
Gross mgn40%
Net mgn-26%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
애드바이오텍 es una empresa que opera en el sector de la salud y farmacéutico, cotizada en el mercado XKRX. Se enfoca en desarrollar soluciones innovadoras para la salud y el bienestar del paciente.